For its third fiscal quarter (ending September 30), Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported a -154% decline in E.P.S. from $1.37 a year ago to $-0.74 in the current quarter. This performance was $-1.36 short of the consensus estimate of $0.62. E.P.S. were $1.06 for the latest four quarters through September 30 versus $0.23 for the same period a year ago — an increase of 361%.
Recent Price Action
On 11/8/23, Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock declined by -1.7%, closing at $52.23. The stock has been weak relative to the market over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, LGND is expected to continue to be a Value Builder.
Ligand Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Ligand Pharmaceuticals has a slightly negative Power Rating of 31 and a slightly negative Appreciation Score of 30, producing the Lowest Value Trend Rating.
Rating Review
In light of this discouraging new earnings information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment